Pro-EU parties are set to hold onto two-thirds of the seats at the EU Parliament.Europe Politicsread more
The projected result comes shortly after Conservative Party leader Theresa May announced her resignation as prime minister on Friday morning.Europe Politicsread more
Stocks in Asia were were mixed in Monday morning trade as investors watched for developments from U.S. President Donald Trump's state visit to Japan as well as results from...Asia Marketsread more
Sources say the talks have picked up speed in recent days and could lead to an announcement regarding a merger or partnership by Monday.Autosread more
Biden had criticized Kim Jong Un as a "dictator" and a "tyrant" at a recent rally in Philadelphia. North Korean state media responded by calling Biden a "fool of low IQ" among...Politicsread more
Book income helped self-proclaimed socialist Bernie Sanders join the millionaire class, a group he has often criticized during his decades in politics.Politicsread more
Exit polls showed National Rally, a re-branding of Le Pen's National Front, beating Macron's party by just one seat.Europe Politicsread more
Stocks that are most prone to swine flu fears include Bloomin' Brands, Phibro, Darling Ingredients, Deere, and Hormel, according to analysts.Marketsread more
Trump was speaking at a meeting of Japanese business leaders in Tokyo during his state visit to Japan on Saturday.Marketsread more
You should use your summer vacation to unwind from work stress. Here are some tips for disconnecting while you're away.Technologyread more
If you value reliability and quality over a posh cabin and jealous looks, the Lexus LX 570 two-row is the Japanese Range Rover you need.Autosread more
As Alnylam Pharmaceuticals nears approval of its first drug, the fledgling drug-maker is planning to transition out of research and development into the commercial stage.
That means figuring out a pricing strategy, and CEO John Maraganore said he supports the idea of pegging increases in drug prices to the rate of inflation.
"It's hard to justify drug price increases," Maraganore said on CNBC's "Power Lunch." If you price a drug appropriately, where it ought to be priced, whats the rationale of increasing the price every year? "
"It's hard for our industry to defend that, overall," he added.
That breaks down to a price increase of approximately 2 to 3 percent yearly, which pales in comparison to increases industry-wide. Drug costs have skyrocketed in recent years, with some prices surging more than 1,000 percent per year.
Companies argue profits from inflated drug pricing help them grow and fund more drug development. Alnylam hopes to take almost the opposite approach, growing through innovation.
"At Alnylam, we've got a really robust product engine. We have the ability of generating, with our platform, a steady flow of new medicines. We just don't have to rely on drug price increases as a way of fueling future growth for the company," he said.
Despite his optimism, the company had high-profile drug failures. Stock struggled late last year when the company was forced to halt development on drug revusiran, after a late-stage study revealed it increased risk of death in test subjects.
Still, Maraganore feels confident that Alnylam's next drug, patisiran, is nearing approval, and the company has a few additional drugs in the pipeline. Stock has responded accordingly, up more than 257 percent year-to-date.
Maraganore also looked ahead to what drug distribution could look like in the near future. Alnylam aims to be there when Amazon makes more decisive moves into the health-care industry, according to the CEO.
"It could be very disruptive from distribution model to have a company like Amazon in the space," Maraganore said. "We welcome a conversation with Amazon to ... understand how we can work together to make sure patients get access to important medicines."